The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes two weeks after J&J ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

Trump's pick for HHS secretary who endured confirmation hearings last week—has repeatedly criticized industry ties to the FDA ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...